Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma.

CONTEXT Oncogenic osteomalacia, a paraneoplastic syndrome associated with hypophosphatemia due to increased urinary phosphate excretion, is caused by excessive synthesis and secretion of fibroblast growth factor 23 (FGF23), a phosphaturic hormone that is normally produced by osteocytes. Most cases of oncogenic osteomalacia have been associated with benign tumors of bone or soft tissue; however, whether malignant neoplasms can also produce and secrete FGF23 is currently unknown. OBJECTIVE The aim was to determine whether a malignant neoplasm could cause oncogenic osteomalacia through excessive production and secretion of FGF23. SETTING We describe an 80-year-old woman with stage IV colon adenocarcinoma who presented with severe hypophosphatemia (0.4 mg/dL; reference, 2.6-4.5 mg/dL). RESULTS Fractional excretion of phosphate was 34% (reference, <5% in the setting of hypophosphatemia), and plasma levels of FGF23 were highly elevated at 674 RU/mL (reference, <180 RU/mL). Immunohistochemical analysis of the patient's tumor showed strong staining for FGF23. Genetic analyses revealed a point mutation in the KRAS gene. CONCLUSIONS We present the first case in which a malignant neoplasm is documented to produce and secrete FGF23, leading to renal phosphate-wasting. Oncogenic osteomalacia should be considered in the differential diagnosis for patients with a malignant tumor who present with hypophosphatemia.

[1]  F. Real,et al.  Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome , 2012, Nature Genetics.

[2]  P. Hoff,et al.  Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition , 2012, Supportive Care in Cancer.

[3]  Rebecca A Betensky,et al.  Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. , 2011, Cancer cell.

[4]  E. Tantisattamo,et al.  Dual paraneoplastic syndromes: small cell lung carcinoma-related oncogenic osteomalacia, and syndrome of inappropriate antidiuretic hormone secretion: report of a case and review of the literature. , 2011, Hawaii medical journal.

[5]  E. Jacobs,et al.  Circulating fibroblast growth factor-23 is associated with increased risk for metachronous colorectal adenoma , 2011, Journal of carcinogenesis.

[6]  T. Shimada,et al.  Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. , 2010, Kidney international.

[7]  K. White,et al.  Genetic Disorders of Phosphate Homeostasis , 2010 .

[8]  R. Pereira,et al.  Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. , 2009, Bone.

[9]  M. Mohammadi,et al.  The parathyroid is a target organ for FGF23 in rats. , 2007, The Journal of clinical investigation.

[10]  E. Giovannucci.  Epidemiological Evidence for Vitamin D and Colorectal Cancer , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  A. Sav,et al.  Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers. , 2007, Journal of gastrointestinal and liver diseases : JGLD.

[12]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[13]  B. Deyoung,et al.  Elevated fibroblast growth factor‐23 in hypophosphatemic linear nevus sebaceous syndrome , 2005, American journal of medical genetics. Part A.

[14]  K. White,et al.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. , 2003, The New England journal of medicine.

[15]  M. Sundaram,et al.  Oncogenic Osteomalacia , 2002, Seminars in musculoskeletal radiology.

[16]  P. Rosen,et al.  Oncogenic osteomalacia associated with prostate cancer. , 1997, The Journal of urology.

[17]  H. Raff,et al.  Case report: renal phosphate wasting, syndrome of inappropriate antidiuretic hormone, and ectopic corticotropin production in small cell carcinoma. , 1995, The American journal of the medical sciences.

[18]  H. Nakahama,et al.  Prostate cancer-induced oncogenic hypophosphatemic osteomalacia. , 1995, Urologia internationalis.

[19]  C. van Heyningen,et al.  A small cell bronchogenic carcinoma associated with tumoral hypophosphataemia and inappropriate antidiuresis. , 1994, Postgraduate medical journal.

[20]  C. McMurtry,et al.  Oncogenic Osteomalacia Associated with Metastatic Prostate Carcinoma: Case Report and Review of the Literature , 1993, Journal of the American Geriatrics Society.

[21]  L. Schumaker,et al.  1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. , 1993, Cancer research.

[22]  J. Benhattar,et al.  Prognostic significance of K-ras mutations in colorectal carcinoma. , 1993, Gastroenterology.

[23]  B. Mazières,et al.  Phosphate diabetes associated with bone metastases of oat cell lung cancer. , 1991, The Journal of rheumatology.

[24]  E. G. Anderson,et al.  Tumour induced hypophosphataemia associated with small cell carcinoma of the bronchus. , 1987, Thorax.

[25]  M. Fallon,et al.  Oncogenic osteomalacia and inappropriate antidiuretic hormone secretion due to oat-cell carcinoma. , 1984, Annals of internal medicine.